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Targeted inhibition of proteins modulating epigenetic changes is an increasingly important
priority in cancer therapeutics, and many small molecule inhibitors are currently being
developed. In the case of neuroblastoma (NB), a pediatric solid tumor with a paucity
of intragenic mutations, epigenetic deregulation may be especially important. In this
study we validate the histone methyltransferase G9a/EHMT2 as being associated with
indicators of poor prognosis in NB. Immunological analysis of G9a protein shows it
to be more highly expressed in NB cell-lines with MYCN amplification, which is a
primary determinant of dismal outcome in NB patients. Furthermore, G9a protein in
primary tumors is expressed at higher levels in poorly differentiated/undifferentiated
NB, and correlates with high EZH2 expression, a known co-operative oncoprotein in
NB. Our functional analyses demonstrate that siRNA-mediated G9a depletion inhibits
cell growth in all NB cell lines, but, strikingly, only triggers apoptosis in NB cells with
MYCN amplification, suggesting a synthetic lethal relationship between G9a and MYCN.
This pattern of sensitivity is also evident when using small molecule inhibitors of G9a,
UNC0638, and UNC0642. The increased efficacy of G9a inhibition in the presence
of MYCN-overexpression is also demonstrated in the SHEP-21N isogenic model with
tet-regulatable MYCN. Finally, using RNA sequencing, we identify several potential tumor
suppressor genes that are reactivated by G9a inhibition in NB, including the CLU, FLCN,
AMHR2, and AKR1C1-3. Together, our study underlines the under-appreciated role of
G9a in NB, especially in MYCN-amplified tumors.
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INTRODUCTION
Neuroblastoma (NB) is a biologically and clinically heterogeneous cancer arising from the
developing sympathetic nervous system. About 25% of NB patients have a very poor prognosis
clinical subtype characterized by amplification of the MYCN proto-oncogene (1–3). Change of
function gene mutations are relatively scarce in NB, but include the oncogene ALK, which is
frequently mutated in familial NB and in up to 10% of sporadic cases (4). This has prompted the
notion that epigenetic aberrations are likely to contribute to NB pathogenesis.
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Consistent with this hypothesis, evidence has accrued for
the involvement of epigenetic modifiers, including histone
methyltransferases (HMTs) in NB tumorigenesis. For example,
we previously showed that knockdown of the HMTs EZH2,
CARM1, or PRMT5 all decreased survival of NB cells (5). High
levels of the MYCN transcription factor leads to activation of
survival/growth genes, but also repression of genes necessary for
terminal differentiation in the sympathetic nervous system (6, 7).
MYCN represses genes driving differentiation and apoptosis by a
variety of means, including recruitment of epigenetic repressors,
such as histone deacetylases (8) and the Polycomb protein
EZH2 (9). EZH2 has been independently shown to repress
tumor suppressor genes in neuroblastoma, including CASZ1,
RUNX3,NGFR, andCLU (10).CLU, encoding Clusterin, has been
characterized as a haploinsufficient tumor suppressor gene in NB
(11). The widespread involvement of HMTs in tumorigenesis has
led to concerted pharmaceutical interest in developing selective
inhibitors for HMTs (12).
Another HMT implicated in NB is G9a (or EHMT2/KMT1C),
the primary function of which is to mono- or di-methylate
histone 3 lysine 9 (H3K9) (13, 14). These methylation marks are
related to transcriptional activation and repression, respectively,
and G9a mediated gene silencing has been shown to be involved
in regulating differentiation of embryonic stem cells (15).
Moreover, G9a has multiple non-histone targets such as p53
(16) and chromatin remodelers Reptin and Pontin (17, 18). In
these cases, the post-translational methylation of proteins can
either inactivate protein function, as in the case of p53, or
in the case of Reptin and Pontin can direct these proteins to
different targets to alter target gene expression. G9a can also
act as a co-factor independent of its HMT activity by binding
to nuclear receptor coactivator GRIP1 and forming a scaffold
complex which in turn can activate downstream targets (19).
G9a is known to be overexpressed in a variety of cancers such
as colorectal (20), bladder (21), hepatocellular (22) carcinomas,
and rhabdomyosarcomas (23), suggesting it is an oncoprotein
and therefore a viable therapeutic target for small molecule
inhibitors. TheG9a inhibitor BIX-01294was one of the first HMT
inhibitors discovered, displaying over 20-fold greater inhibition
of G9a compared to the closely related HMT GLP (EHMT1).
This inhibitor also showed no activity against a panel of HMTs
including PRMT1, SUV39H1, SET7/9 and ESET, and was able to
reduce demethylated H3K9 (H3K9me2) levels in chromatin (24).
A second generation inhibitor UNC0638 is a potent and highly
selective probe for G9a and GLP (>500-fold selectivity over other
histone methyltransferases) and has a high toxicity/function
ratio of >100 (25). UNC0642 has improved pharmacokinetic
properties and is suitable for use in vivo (26). UNC0638 and
UNC0642 act as competitive substrate inhibitors, thus blocking
the SET domain from acquiring methyl groups from its S-
adenosyl-methionine (SAM) cofactor. Further inhibitors are also
being developed (27).
Three previous studies have alluded to the possibility of
G9a as a therapeutic target in NB. On the basis of microarray
database analysis, Lu et al. proposed that G9a may be oncogenic
in NB, and further showed that G9a knockdown or BIX-01294
treatment led to apoptosis in three NB cell-lines (28). In contrast,
two other studies suggested that G9a knockdown or BIX-01294
treatment could trigger autophagic cell death (29–31), and that
G9a-mediated epigenetic activation of serine-glycine metabolism
genes is critical in oncogenesis. Taken together, these papers agree
that inhibiting G9a may be beneficial for NB therapy, but the
mode of action is unclear. In addition, the more selective second
generation of G9a inhibitors such as UNC0638 and UNC0642
have not been evaluated.
In this study, we comprehensively assess the association of
G9a with key prognostic factors in NB, specifically differentiation
status and MYCN over-expression. We further evaluate
UNC0638 and UNC0642 as potential therapeutic agents for NB,
and identify putative tumor suppressor genes that are repressed
by G9a in NB. Our data strongly suggest that G9a inhibition
may be especially beneficial for poor-prognosis NB driven by
MYCN amplification.
MATERIALS AND METHODS
Neuroblastoma Cell Lines and Culture
Conditions
Neuroblastoma cell lines were kindly supplied by Prof. Deborah
Tweddle (Newcastle University), Prof. Manfred Schwab
(German Cancer Research Center), Robert Ross (Fordham
University), and the Childrens Oncology Group (Texas Tech
University Health Sciences Center) or purchased from Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ).
Cell lines were cultured in Dulbecco’s modified eagle’s medium
(DMEM):F12-HAM (Sigma) supplemented with 10% (v/v) fetal
bovine serum (FBS) (Life technologies), 2mM L-glutamine,
100 U/mL penicillin, 0.1 mg/mL streptomycin, and 1% (v/v)
non-essential amino acids. SH-EP-Tet21N (RRID:CVCL_9812)
cells were cultured in RPMI 1640 (Gibco), supplemented with
10% (v/v) tetracycline-free FBS (Life technologies), 2mM
L-Glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin,
and 1µg/mL tetracycline. Cell counts and cell viability were
assessed using Countess automated cell counter and trypan
blue (Thermo Fisher Scientific). Transient knockdowns were
performed by using short interfering RNA (siRNA), targeting
G9a/EHMT2 (5′-GAACAUCGAUCGCAACAUCdTdT-
3′/5′-GAUGUUGCGAUCGAUGUUCdTdT-3′) in a reverse
transfection protocol, with 50 nM siRNA and Lipofectamine
RNAiMAX (Invitrogen), both diluted in OptiMEM
media (Invitrogen). Non-targeting siRNAs were used as
control (5′-UGGUUUACAUGUUUUCUGAdTdT-3′/5′-
UCAGAAAACAUGUAAACCAdTdT-3′). For G9a inhibition,
attached cells were treated with BIX-01294 (Tocris), UNC0638,
(Tocris) and UNC0642 (Tocris) dissolved in DMSO, at the
indicated concentrations.
MTT Cell Viability Assay
NB cells were seeded in 96 well-plates and treated the next day in
triplicate with a serial dilution of UNC0638/0642. After 72 h, we
added 10 µL of MTT (5 mg/mL) (Sigma), followed by 50 µL of
SDS lysis buffer (10% SDS (w/v), 1/2500 (v/v) 37% HCl) after a
further 3 h. Following an overnight incubation at 37◦C, the plates
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were read at 570 and 650 nm, using SpectraMax 190 plate reader
(Molecular Devices).
Protein Extraction and Western Blot
Floating and attached cells were lysed in
Radioimmunoprecipitation assay (RIPA) buffer. Protein
concentration was determined by using Micro BCA TM protein
assay kit (Thermo Fisher). Immunoblotting was performed
as described previously (5). The following antibodies were
used to detect G9a (ab185050, Abcam, RRID:AB_2792982),
cPARP (ab32064, Abcam, RRID:AB_777102), MYCN (B8.48,
Santa Cruz, SC-53993, RRID:AB_831602), cCaspase 3 (9664,
Cell Signaling Technology, RRID:AB_2070042), LC3B
(L7543, Sigma, RRID:AB_796155), histone H3 (ab10799,
Abcam, RRID:AB_470239), dimethyl K9 histone H3 (ab1220,
Abcam, RRID:AB_449854), and β-Actin (A3854, Sigma,
RRID:AB_262011), according to manufacturer’s instructions.
RNA Extraction, Reverse Transcription and
qPCR
RNA was extracted from attached cells by using RNeasy Plus
or miRNeasy kits (QIAGEN) according to manufacturer’s
instructions and subsequently transcribed into cDNA
with Superscript IV (Invitrogen). Quantitative PCR was
performed by using QuantiNova kit on Mx3500P PCR
machine (Stratagene). The following oligonucleotide primers
were used to detect target gene expression: AMHR2 F: 5′-
TACTCAACCACAAGGCCCAG-3′, R: 5′-GGTCTGCATCCCA
ACAGTCT-3′, FLCN F: 5′-TCTCTCAGGCTGTGGGAGC-3′,
R: 5′-CCAGCATGCGGAAAGAAG-3′, AKR1C1 F: 5′-CCTA
AAAGTAAAGCTTTAGAGGCCACC-3′, R: 5′-GAAAATGAA
TAAGGTAGAGGTCAACATAAT, AKR1C2, F- CCTAAAAGT
AAAGCTCTAGAGGCCGT-3′, R: 5′-GAAAATGAATAAGA
TAGAGGTCAACATAG-3′, AKR1C3 F: 5′-CTGATTGCC
CTGCGCTAC-3′, R: 5′-TCCTCTGCAGTCAACTGGAAC-3′,
CLU F: 5′-AGCAGCTGAACGAGCAGTTT-3′, R: 5′-AGCTT
CACGACCACCTCAGT-3′, TBP F: 5′-AGCCACGAACCAC
GGCACTGAT-3′, R: 5′-TACATGAGAGCCATTACGTCGT-3′,
ALK F: 5′-CGACCATCATGACCGACTACAA-3′, R: 5′-CC
CGAATGAGGGTGATGTTTT-3′.
Cell Cycle Analysis
Propidium-iodide labeling and fluorescence activated cell sorting
analysis to detect cell cycle phases was performed as previously
described (5).
Immunohistochemistry
Tissue microarrays (TMAs), containing 50 peripheral
neuroblastic tumors were stained using antibodies for EZH2
(NCL-L-EZH2, Novocastra) and G9a/EHMT2 (EPR4019(2),
Abcam, RRID:AB_2687583). Immunohistochemistry was
independently scored by two pathologists blinded to the
specimens, and a score of 1–4 was assigned based on proportion
of positive cells (0, no staining; 1, sporadic staining of individual
cells; 2, <20% of cells stained; 3, 20 to 50% of cells stained;
4, >50% of cells stained). All human tissues were acquired
with appropriate local research ethics committee approval.
Immunohistochemistry was performed with a LeicaMicrosystem
Bond III automated machine using the Bond Polymer Refine
Detection Kit (Ref DS9800) followed by Bond Dab Enhancer
(AR9432). The slides were dewaxed with Bond Dewax Solution
(AR9222). Heat mediated antigen retrieval was performed using
Bond Epitope Retrieval Solution for 20 min.
RNA-seq and Bioinformatic Analysis
LAN-1 (RRID:CVCL_1827) cells were treated with 3µM
BIX-01294 and DMSO vehicle as control for 72 h and
were subsequently harvested. RNA was extracted by using
miRNeasy Mini Kit (Qiagen), according to manufacturer’s
instructions. Libraries were constructed and sequenced as
previously described (32). Briefly, cDNA libraries were prepared
from 1 ug RNA (TruSeq Stranded Total RNA Library Prep
Kit, Illumina) and 100 bp, paired end reads were sequenced
on Illumina HiSeq 2000. The reads were aligned to the human
genome (hg38) by using TopHat2 (v2.0.14) and the alignment
files (BAM) were further analyzed in SeqMonk v1.45. (https://
www.bioinformatics.babraham.ac.uk/projects/seqmonk/). Gene
expression was quantified by using the Seqmonk RNA-seq
analysis pipeline. Differentially expressed genes (DEG) were
identified by DESEQ2 (p< 0.005) and aminimum fold difference
threshold of 1.3 was applied. RNA sequencing data is available
from the European Nucleotide Archive (ENA) under the study
accession number PRJEB35417. We performed Gene Signature
Enrichment Analysis (GSEA) on a preranked list of log2-
transformed relative gene expression values (Broad Institute).
Kaplan Meier survival analysis, indicating the prognostic value
of the expression of genes or metagenes was performed by using
the Kaplan scan tool in R2 Genomics Analysis and Visualization
Platform (http://r2.amc.nl).
RESULTS
G9a Expression Correlates With Poor
Prognosis and MYCN Amplification in NB
We first assessed the expression of G9a/EHMT2 in an RNA-seq
dataset of 498 primary NBs (the SEQC dataset, GSE62564)
(33) using the R2: Genomics Analysis and Visualization
Platform (http://r2.amc.nl). Kaplan–Meier analysis of overall
survival showed that high G9a/EHMT2 expression was
significantly associated with poor survival (Figure 1A).
Moreover, G9a/EHMT2 has a significantly increased expression
in MYCN-amplified (MNA) NBs (Figure 1B). In order to
assess whether this relationship at the RNA level was also
apparent at the protein level, we conducted immunoblotting
of G9a protein expression in NB cell lines with and without
MNA, and confirmed that increased G9a protein expression
was apparent in MNA NB cell lines (Figures 1C,D). We next
examined G9a protein expression in a tissue microarray of 50
primary neuroblastic tumors, in parallel with EZH2, which
is known to be involved in NB. Strikingly, expression of G9a
and EZH2 was barely detectable in the more differentiated
ganglioneuromas and ganglioneuroblastomas, generally
regarded as low risk tumors (Figures 2A). However, high nuclear
expression of both G9a and EZH2 was observed in the poorly
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FIGURE 1 | G9a mRNA and protein expression correlate with poor prognosis and MYCN amplification. (A) Kaplan–Meier analysis showing that high expression of
G9a correlates with poor prognosis in primary NB (SEQC, GSE62564). Bonferroni-corrected p-values of log rank test are shown. (B) Significantly higher G9a mRNA
expression is observed in MNA neuroblastoma relative to non MNA. The p-values are calculated by one-way ANOVA. (C) Immunoblot of G9a protein expression in a
panel of MYCN-amplified and non- amplified NB cell lines. β-Actin is used as a loading control. Representative of n = 3. (D) Scatter dot plot of relative G9a protein is
generated from semi-quantitative densitometry of blots from (C). G9a protein expression is higher in MNA neuroblastoma when normalized to β-Actin. Significance
measured by unpaired T test (*p < 0.05).
differentiated and undifferentiated tumors, which are commonly
associated with higher risk and poor outcome. Accordingly, G9a
immunopositivity strongly correlated with the differentiation
status of neuroblastic tumors (Figure 2B). The few G9a positive
cells in the more differentiated tumors were all undifferentiated
neuroblasts, underlining the link between differentiation status
and G9a expression. Scoring the tumors for G9a and EZH2
expression according to the percentage of immunopositive cells
revealed that G9a and EZH2 scores were very highly correlated
(R = 0.76, p = 1.45e-10, Figure 2C), indicative of a potential
functional interplay between these HMTs. Unfortunately, MYCN
status was available for only a few tissue microarray samples,
therefore not sufficient for statistical analysis. Nevertheless, our
expression analyses at the RNA and protein levels shows that
G9a over-expression is associated with poor prognosis NB and
MYCN/EZH2 status.
Short Interfering RNA Mediated G9a
Depletion Leads to Apoptotic Cell Death in
MNA Neuroblastoma Cells
As there is increased expression of G9a in MNA neuroblastoma
cell lines, we next evaluated the effect of short-interfering
RNA (siRNA) mediated G9a depletion on three MNA cell
lines and three non-MNA cell lines. Quantification of adherent
and floating cells following knockdown of G9a in MNA Kelly
(RRID:CVCL_2092), LAN-1 (RRID:CVCL_1827), and SK-N-
BE(2)C (RRID:CVCL_0529) showed a consistent increase in
the percentage of dead cells (p < 0.05) and decrease in the
number of live cells in the population (Figure 3A). In order
to assess the mode of reduced cell survival, immunoblotting
was carried out with markers for apoptosis (cleaved PARP and
cleaved caspase 3) and autophagy (LC3B). In all three MNA lines,
apoptotic cell death was verified by the increase in apoptosis
markers (Figure 3A, lower panel). In contrast, no increases in
LC3B were apparent, suggesting little or no effect on autophagy.
Knockdown in the presence of QVD, a caspase inhibitor,
led to decreased floating cells after G9a knockdown, and, as
expected, no apoptotic markers (Supplementary Figures 1A,B).
MYCN protein also decreased considerably after G9a knockdown
in all three MNA lines. Cell cycle analysis of Kelly cells
after G9a knockdown demonstrated a significant increase
of cells in G1 and a decrease of cells entering S-phase
(Supplementary Figure 1C).
In contrast to these effects in MNA cell-lines, G9a depletion-
associated cell death was not seen in the three non-MNA
cell lines tested [SH-EP (RRID:CVCL_0F47), GI-ME-N
(RRID:CVCL_1232), and SK-N-AS (RRID:CVCL_1700)], as
there was no significant increase in the percentage of dead
cells seen following the depletion. Despite this, decreased
proliferation of these lines was indicated by a significant
decrease in the number of live cells (Figure 3B). The observed
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FIGURE 2 | Immunohistochemical detection of G9a and EZH2 in primary NBs. (A) Haematoxylin and Eosin staining, G9a and EZH2 immunohistochemistry of
neuroblastic tumors. (GN, ganglioneuroma; DIFF NB, differentiating neuroblastoma; PD NB, poorly differentiated NB; UD NB, undifferentiated NB; MNA, MYCN
amplified). (B) Positive staining for G9a correlates with INPC differentiation status of neuroblastic tumors. (C) Immunopositivity was scored based on the proportion of
positive cells (0, no staining; 1, sporadic staining of individual cells; 2, <20% of cells stained; 3, 20 to 80% of cells stained; 4, >80% of cells stained). The proportion
of G9a and EZH2 positive cells strongly and significantly correlated in neuroblastic tumors.
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FIGURE 3 | Apoptotic cell death following G9a depletion is dependent on MYCN. (A) Floating and adherent cells from MNA cell lines were harvested and counted by
trypan blue inclusion assay following G9a depletion. The left-hand graph of each cell line shows the percentage dead cells between the G9a depleted and negative
control. The right-hand graph shows the live cell count of the cells harvested, which is used as a proxy for cell growth. Significant changes are measured the asterisks
(*p < 0.05, ***p < 0.01, ns, not significant, n = 3). Error bars show the SEM. For each cell line, an immunoblot showing effective depletions, apoptosis and autophagy
markers is shown below. β-Actin is used as loading control. The blots are representative of n = 3. (B) Live and dead cell counts and Western blots in non-MNA
cell lines.
lack of cell death was confirmed by immunoblots showing
no change in apoptotic markers cleaved PARP and caspase 3
(Figure 3B). Variable effects on LC3B were observed, increasing
after knockdown in SH-EP cells and decreasing in GI-ME-N
and SK-N-AS cell-lines. Taken together, our analysis of NB cell
lines strongly suggests a requirement on G9a for cell survival of
MNA NB.
To confirm the G9a dependency of MYCN over-expressing
NB cells, G9a depletion was evaluated in isogenic SH-EP-
Tet21N (S21N, RRID:CVCL_9812) cells with Tet-inducible
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FIGURE 4 | G9a depletion leads to cell death in MYCN induced S21N cells
only. (A) Floating and adherent cells from S21N cells, with and without MYCN
induction, were harvested and counted by trypan blue inclusion assay
following G9a depletion as previously. (B) Immunoblot of G9a and apoptosis
and autophagy markers. (*p < 0.05, ***p < 0.01, ns, not significant, n = 3).
MYCN expression. With MYCN induced, G9a depletion led to a
significant increase in the percentage of dead cells, whereas there
was no change in cells without MYCN induction (Figure 4A). As
before, this was despite a significant decrease in live cell count
that occurred across both induced and non-inducedMYCNS21N
cells. This was further confirmed by the immunoblots showing
that G9a depletion led to an increase in apoptosis markers in
the MYCN induced cells only (Figure 4B). These experiments
further emphasize the G9a dependency ofMYCN-overexpressing
NB cells.
MNA NB Cell Are More Sensitive to G9a
Inhibitors UNC0638 and UNC0642
As our genetic interference analyses demonstrate that NB cells
may be vulnerable to decreased G9a activity, we treated a
panel of 13 NB cell lines and 2 two disease-free control cell
lines with G9a SMIs and conducted cell survival assays. Whilst
all NB cell lines exhibited reduced viability upon treatment
with UNC0638 (Figure 5A) and UNC0642 (Figure 5B) in a
concentration dependent manner, there was no effect on the
disease-free lines RPE-1 and NF-TERT. Importantly, consistent
with our genetic interference data, a clear pattern of greater
sensitivity of MNA lines was observed. For UNC0638, the
average IC50 was 8.3µM for MNA lines, compared to 19µM
for non-MNA lines (p < 0.01). Similarly, for UNC0642 the
average IC50s were 15 and 32µM for MNA and non-MNA lines,
respectively (Figures 5C–F). As expected, treatment with both
inhibitors led to decreased histone H3 lysine 9 dimethylation
(Supplementary Figure 2).
Next, UNC0638 and UNC0642 were evaluated in S21N cells
to further assess the association of MYCN over-expression and
sensitivity to pharmaceutical G9a inhibition. S21N cells with
induced (high) MYCN were more sensitive to G9ai by UNC0638
and UNC0642 than the uninduced cells (Figures 5G,H). As with
the cell-line panel, UNC0638 was slightly more potent than
UNC0642, with the IC50 values for MYCN induced cells being
5.7 and 10.6µM, respectively, compared to 16.6 and 23.2µM for
uninduced S21N cells (Figure 5I). All the IC50 values for the cell-
lines analyzed are detailed in Table 1. Thus, our pharmaceutical
inhibition assays reflect our genetic interference data, showing
that NB cell-lines are sensitive to both UNC0638 and UNC0642,
with MYCN over-expressing cells being significantly more
sensitive than non-MNA lines.
UNC0638 Leads to Increased Apoptosis
Specifically in MNA NB Lines
G9a knockdown analyses demonstrated that only MNA NB lines
underwent programmed cell death, despite all lines showing
some degree of growth inhibition. To determine if the effects
on cell death and proliferation following G9a drug inhibition are
akin to the results following G9a depletion as shown in Figure 3,
three MNA and three non-MNA NB cell lines were treated
with UNC0638 and cell growth effects quantified, together
with an assessment of apoptosis and autophagy markers. The
three most sensitive MNA lines, Kelly, IMR-32, and LAN-1
all showed a significant increase in the percentage of dead
cells following treatment (Figure 6A). Apoptosis was verified by
immunoblotting, all 3 treated lines showing an increase in cleaved
PARP and caspase 3 (Figure 6A, lower panel). Although Kelly
and LAN-1 cells showed some increase in LC3B, IMR-32 cells
exhibited a decrease of LC3B. As with knockdowns, all 3 MNA
lines showed a decrease in MYCN protein.
Conversely, in the three non-MNA lines, SH-EP, GI-M-
EN, and SH-SY5Y, there was no significant change in the
percentage dead cells. However, there was a significant decrease
in the number of live cells counted following the treatments
(Figure 6B). There was no change in the apoptotic markers
after UNC0638 treatment; however, there was an increase
in the autophagy marker LC3B in all three non-MNA cell-
lines. Together these experiments mirror the G9a depletion
experiments with respect to increased apoptosis and efficacy in
MNA cell-lines.
Using the S21N model, we further evaluated the requirement
for MYCN over-expression in apoptosis triggered by UNC0638.
Although there was no increase in the percentage of dead
cells without MYCN induction, a significant 2-fold increase in
dead cells was apparent in the presence of MYCN induction
(Figure 7A). Immunoblotting showed that the autophagymarker
LC3B was increased following UNC0638 treatment regardless
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FIGURE 5 | Sensitivity of neuroblastoma cell-lines to G9a inhibitors UNC0638 and UNC0642. (A) Thirteen neuroblastoma cell lines, including six MYCN-amplified
(shades of red lines), seven non-MYCN-amplified (shades of black lines), and two non-cancerous cell lines (shades of green lines) were screened by MTT based cell
proliferation assay after 72 h to determine sensitivity to G9a SMI UNC0638. 0.0µM was plotted as 0.1µM, to be able to chart on log scale. Error bars show SEM. n ≥
3. (B) MTT assay of 13 NB and two normal cell lines using G9a SMI UNC0642. (C) Bar chart of IC50 values for UNC0638 with all cell lines. Error bars show SEM. (D)
Bar chart of IC50 values with UNC0642. Error bars show SEM. (E) MTT assay based IC50 values for UNC0638 from (A) are visualized as a scatterplot between MNA
and non-MNA cell lines. Error bars show the SEM. ***p < 0.01, unpaired t test. (F)—MTT assay based IC50 values for UNC0642 from (B) are visualized as a
scatterplot between MNA and non-MNA cell lines. Error bars show the SEM. ***p < 0.01, unpaired t-test. (G) S21N cell line with and without induced MYCN were
screened by MTT based cell proliferation assay after 72 h to determine sensitivity to G9a inhibitors UNC0638. 0.0µM was plotted as 0.1µM to chart on log scale.
Error bars show SEM. N = 3. (H) MTT assay of induced and uninduced S21N cells using UNC0642. (I)—Bar chart of S21N IC50 values with and without induction.
Error bars show the SEM. ***p < 0.01, unpaired t-test.
of MYCN levels. The apoptosis markers, however, were only
increased by UNC0638 in the presence of MYCN over-
expression, further confirming the requirement for G9a activity
for the survival of MYCN over-expressing cells (Figure 7B). This
further supports G9a activity for targeted therapeutics in NB,
especially for patients withMYCN amplification.
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TABLE 1 | IC50 values of NB cell lines with G9a inhibitors UNC0638 and
UNC0642.
Cell line Drug concentration (µM)
UNC0638 ± SEM UNC0642 ± SEM
Kelly 2.2 ± 0.1 4.3 ± 0.7
LAN-1 5.4 ± 0.7 15.4 ± 1.7
IMR-32 8.1 ± 0.3 14.3 ± 1.0
LAN-5 10.3 ± 3.2 17.6 ± 5.1
NGP 10.1 ± 1.3 20.2 ± 1.7
SK-N-BE(2)C 13.7 ± 2.0 20.1 ± 3.6
LAN-6 13.1 ± 2.9 21.6 ± 0.1
NBL-S 13.2 ± 1.7 19.4 ± 4.3
SH-SY5Y 16.1 ± 0.3 29.1 ± 0.7
SH-EP 16.2 ± 1.0 29.6 ± 0.5
SH-IN 16.8 ± 2.0 30.1 ± 2.6
SK-N-AS 28.3 ± 3.8 48.2 ± 6.0
GI-ME-N 29.9 ± 1.4 51.0 ± 1.4
S21N (MYCN ON) 5.7 ± 0.7 10.6 ± 1.5
S21N (MYCN OFF) 16.6 ± 2.1 23.2 ± 3.8
Values are means ± SEM of n ≥ 3. MNA cell lines are colored red.
Identification of Genes Regulated by G9a
Inhibition in NB
We next sought insight into gene expression changes inMNANB
cells following G9a inhibition. For this, we treated LAN-1 cells
with BIX-01294, as this inhibitor would facilitate comparison
with previous studies on G9a in NB, including one attributing
drug activity to changes in the expression of genes involved in
serine metabolism. Using RNA sequencing, we identified 115
genes whose expression level was altered by more than 1.3-fold,
at p < 0.005. Consistent with the role of G9a in epigenetic
repression, the majority of these genes were upregulated after
BIX-01294 treatment, but approximately a third of affected
genes were down-regulated (Figure 8A). The magnitude of gene
induction was generally much higher than the changes in down-
regulated genes, with 11 genes being upregulated between 10
and 100-fold more than vehicle treated cells. In contrast, down-
regulated genes were decreased by a maximum of approximately
5-fold. We have not detected changes in the genes of the serine-
glycine pathway as previously described (29) which may be due
to differences in culture conditions, namely supplementation
with non-essential amino acids. A full list of genes showing
altered expression is given in Supplementary Table 1. Gene set
enrichment analysis (GSEA) verified a profound effect on gene
sets driven by the MYC family; in particular the MYCN-157
signature of genes associated with poor prognosis in NB (34)
was profoundly affected. MYCN induced genes from this data
set were downregulated by BIX-01294, whereas MYCN repressed
genes were upregulated (Figure 8B). GSEA also showed that
apoptosis gene sets were upregulated, together with gene sets
including genes epigenetically silenced by EZH2 and histone
deacetylases 1 and 3 (HDAC1 and HDAC3) (Figures 8C,D).
These analyses suggest that G9a inhibition may be effective in
altering oncogenic gene expression programmes in MNA NB.
In order to further assess the alteration of oncogenic potential
by G9a inhibition, we constructed metagenes corresponding
to BIX-01294 upregulated and downregulated genes. These
metagenes act as quantifiable model genes enabling the
association with prognosis of grouped up/down regulated
genes. As shown in Figure 8E, high expression of BIX-01294
upregulated genes correlate with good overall outcome, and
low expression of these genes correlates with poor prognosis.
Conversely, high expression of BIX-01294 down-regulated genes
correlates with poor overall outcome, and low expression of
these genes correlates with good prognosis (Figure 8F). This
strongly suggests that G9a represses tumor suppressor genes in
NB that can be reactivated by BIX-01294 treatment. The data also
suggests that G9a supports activation of genes associated with NB
development, including MYCN regulated genes.
Lastly, we validated some of the top genes identified after
BIX-01294 treatment of LAN-1 cells in two MNA (LAN-
1 and Kelly) and two non-MNA NB (GI-M-EN and SK-N-
AS) cell-lines treated with UNC0638. As shown in Figure 8G,
CLU, AMHR2, FLCN, and AKR1C1-3 were all upregulated
to varying extents following UNC0638 treatment, confirming
good concordance between the actions of BIX-01294 and
UNC0638. We also confirmed down-regulation of the ALK
oncogene, revealed by our RNA sequencing, with UNC0638.
The association between expression of individual genes and
clinical prognosis is summarized in Supplementary Table 1,
strongly suggesting that our BIX-01294/UNC0638 validated
genes, AMHR2, FLCN, and AKR1C1-3 are amongst many
novel NB tumor suppressor genes found by our analysis.
CLU, encoding clusterin, is already a known NB tumor
suppressor gene (11) known to be repressed by MYCN and
EZH2 (10, 34).
Taken together, our data strongly support small molecule
inhibition of G9a as a therapeutic intervention for NB, in
particular theMYCN-amplified subgroup.
DISCUSSION
Whilst the potential of targeting the epigenetic machinery
for cancer therapy is increasingly recognized (35), and over-
expression of G9a has been reported in many cancers (36),
targeted inhibition of G9a is relatively understudied. In the
context of neuroblastoma, three papers have examined the
impact of G9a knockdown and the small molecule inhibitor BIX-
01294 on cell proliferation and cell death (28–30). However,
the effect and potential benefits of targeting G9a in NB remain
unclear due to limited analysis of the G9a protein in NB,
activities and pathways regulated by G9a, and the absence of
assessment of second-generation inhibitors of G9a toward NB
cells. In this study, we have examined G9a expression in relation
to NB disease stratifying factors, and also assessed three G9a
inhibitors. Based on our findings, as discussed below, we propose
that pharmaceutical inhibition of G9a is a viable therapeutic
approach, especially for NB driven byMYCN amplification.
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FIGURE 6 | UNC0638 specifically induces apoptosis in MNA neuroblastoma cell-lines. (A) Floating and adherent cells from MNA cell lines were harvested and
counted by trypan blue inclusion assay following 5–10µM UNC0638 treatment for 72 h. The left-hand graph of each cell line shows the percentage dead cells, while
the righthand graph shows the live cell counts, which was used as a proxy for cell growth. Significant changes are indicated by asterisks (***p < 0.01, n = 3). Error
bars show the SEM. Western blots for each cell line show markers for cell death, autophagy markers and MYCN. β-Actin is used as loading control (representative of
n = 3). (B) Live and dead cell counts and Western blots of non-MNA cells after treatment with 10µM UNC0638 for 72 h (*p < 0.05, ns not significant, n = 3).
Our immunohistochemical analysis of G9a in NB shows for
the first time that nuclear G9a is markedly increased in poorly
differentiated and undifferentiated NB, as also suggested by
our mRNA database mining and immunoblotting of thirteen
NB cell-lines. Two other potentially critical associations were
revealed by these studies, (i) elevated G9a in MNA cell-lines,
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FIGURE 7 | UNC0638 leads to apoptosis of MYCN overexpressing S21N
cells. (A) Floating and adherent cells from S21N cells with and without induced
MYCN were harvested and counted by trypan blue inclusion assay following
5µM UNC0638 treatment at 72 h. The charts show the percentage dead and
live cells between treated and control. Error bars are SEM. (*p < 0.05, ns not
significant, n = 3). (B) Western blot of induced and uninduced S21N cells
treated with 5µM UNC0638 for 72 h.
and (ii) correlated expression between EZH2 and G9a in primary
tumors. Interestingly, G9a has been shown to stabilize c-Myc
in immune cells and thereby contribute to the regulation of
inflammation (37). More recently, this association was also
reported in breast cancer cell lines, with the Myc-G9a complex
being crucial for Myc-mediated gene repression (38). Thus,
it is possible that G9a may regulate MYCN in an analogous
manner by modulating MYCNs transcriptional activity. G9a may
also act similarly to PRMT5, which we have shown to directly
methylate MYCN and regulate its stability at the protein level (5).
The need for further in-depth analyses to explore the possible
interplay of G9a and MYCN proteins is underlined by our
expression data, as well as functional and transcriptomic data
(see below).
The correlation of G9a and EZH2 expression is also
important when considering possible epigenetic therapeutics
for NB. Although G9a is mainly known to catalyze H3K9
dimethylation, it can also methylate H3K27 (39) and it has
been shown to be a key regulator of Polycomb repressor
Complex 2 (40). In addition, it was shown in breast cancer
cells that effective gene re-expression necessitated the inhibition
of both G9a and EZH2. For example, dual depletion of
G9a and EZH2 dramatically increased SPINK1 mRNA when
individual depletion had no effect. This dual inhibition was
also shown to increase growth inhibition over only G9a or
EZH2 single inhibition (41). Given the increasing evidence for
EZH2 involvement in NB, especially in tandem with MYCN
(9, 10, 42, 43), there is clearly a rationale for deploying G9a
and EZH2 inhibitors together for the treatment of NB. This is
further emphasized by the reactivation of the CLU gene by all
the G9a inhibitors shown in our studies, as it is a NB tumor
suppressor gene known to be regulated by EZH2 and MYCN
(10, 11, 34).
Our evaluation of UNC0638 and UNC0642 showed that
both inhibitors have a more pronounced growth-inhibitory
effect on MNA NB cell-lines. Furthermore, functional analysis
of genetic and pharmaceutical inhibition of G9a revealed
a striking correlation between MYCN over-expression and
apoptosis triggered by G9a inhibition. This clarifies to some
extent the previous contradictions regarding autophagy and
apoptosis resulting from G9a inhibition in NB (28–30).
More importantly, it alludes to a synthetic lethal relationship
(44) between G9a and MYCN expression in MNA NB.
Whilst the mechanisms underlying this remain to be fully
elucidated, our RNA sequencing suggests that a simultaneous
combination of effects on MYCN control of gene expression
and epigenetic derepression are strongly involved. G9a is also
known to be involved in the DNA damage response, with
UNC0638 potentiating the cytotoxicity of DNA damaging
agents (45). It is therefore possible that cells over-expressing
MYCN have greater replicative stress and are therefore
more susceptible to an impairment/inhibition of the DNA
damage response. Although G9a is also known to regulate
the p53 protein by post-translational methylation (16),
our data showing that the TP53 wild-type cell line IMR-
32 shows comparable sensitivity to other MNA cell-lines
(containing TP53 mutations) suggests that the p53 pathway
is not directly involved in growth inhibition induced by the
G9a inhibitors.
Our RNA sequencing following BIX-01294 treatment revealed
upregulation of the established NB tumor suppressors CLU,
but also other putative tumor suppressors not previously
associated with NB. One example of this is the FLCN gene,
encoding folliculin. Folliculin has been shown to regulate AMP-
activated kinase (AMPK), which enables regulation of cancer
cell metabolism and also autophagy (46, 47). Notably, our
upregulated genes also included FNIP1 and FNIP2, encoding
folliculin-interacting proteins 1 and 2, emphasizing the potential
importance of this pathway in NB tumor suppression. Other
putative tumor suppressor genes include AMHR2, encoding
Anti-Mullerian Hormone Receptor Type 2, also known as
Mullerian Inhibiting Substance Type II Receptor. AMHR2 has
been shown to suppress tumorigenicity in the testes (48).
The aldo keto-reductase 1 family genes (AKR1C1-3) encode
steroidogenic genes which, although expressed at high levels in
some cancers (49), are also downregulated in others such as
breast and gastric cancers (50, 51). Of the down-regulated genes,
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FIGURE 8 | RNA sequencing of BIX-01294 treated LAN-1 cells identifies G9a regulated genes. (A) Heatmap of differentially expressed genes (DEGs) in biological
replicate treatments of LAN-1 NB cells by 3µM BIX-01294 for 72 h, (p < 0.005, minimum fold change 1.3). (B) Gene set enrichment analysis (GSEA) showing reversal
of MYC/MYCN-driven transcriptomic changes. The MYCN-157 gene sets were derived from Valentijn et al. (34). (C) GSEA indicating upregulation of gene sets
associated with apoptosis and (D) repression by EZH2, HDAC1 and HDAC3. (E) Kaplan–Meier survival analyses showing that high expression of genes upregulated
by BIX-01294 treatment in LAN-1 correlates with good prognosis in an expression data set of 498 primary NB tumors (SEQC, GSE62564), while (F) high expression
of BIX-01294 downregulated genes correlates with poor prognosis. (G) Validation of DEG in MNA NB cell lines, LAN1 and Kelly, and non-MNA cells, GI-M-EN and
SK-N-AS, after treatment with G9a inhibitor (5–10µM UNC0638 for 24 h).
several were histone genes, probably reflecting the decreased G1
to S-phase progression in cells treated with inhibitors. The ALK
gene was also decreased, possibly as a result of decreased MYCN;
ALK and MYCN are known to mutually regulate each other in
NB (52, 53). Whilst our study does not establish a direct causal
link between G9a, MYCN and ALK, it is interesting to note that
the two cell-lines most sensitive to UNC0638 are representative
of “ultra-high risk” NB, having both MYCN amplification and
activating mutations of ALK.
In summary, this paper highlights a previously unrecognized
therapeutic vulnerability of neuroblastomas with MYCN
amplification to small molecule inhibitors of G9a, As MYCN
is also a known driver of several other cancers, this work
underlines the need for future work on these cancers with
current inhibitors, and the development of next generation
G9a inhibitors. Our study also rationalizes the combined
pharmacological targeting of G9a and EZH2 for neuroblastoma
in the future.
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